When time is precious

Initiating Drogenil for metastatic cancer patients could optimise not only time to progression and survival time but also the quality of that life.1,6

As monotherapy, Drogenil is comparable to castration in terms of survival time,1,7 and unlike castration, Drogenil patients can keep their libido and potency,3,5 helping them to sustain a loving relationship.

Drogenil is the only non-steroidal anti-androgen recommended for monotherapy.

As part of combination therapy in maximal androgen blockade (MAB), of all the anti-androgens, including the recently launched bicalutamide, only Drogenil has proven survival advantage over orchidectomy or medical castration1,2 – offering patients the chance of more precious time.

FOR LIVING WITH PROSTATE CANCER